Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 2, 2005, Pages 200-210

  Kim, Chunghui ^a,c   Kim, Nari ^a   Joo, Hyun ^a   Youm, Jae Boum ^a   Park, Won Sun ^a   Van Cuong, Dang ^a   Park, Young Shik ^a   Kim, Euiyong ^a   Min, Churl Ki ^b   Han, Jin ^a  

^a Inje University   (South Korea)

^b Ajou University   (South Korea)

^c Gyeongsang National University   (South Korea)

Author keywords

Adriamycin; Antitumor activity; Cardiotoxicity; Melatonin; Nuclear DNA fragmentation

Indexed keywords

CELL NUCLEUS DNA; DNA FRAGMENT; DOXORUBICIN; MELATONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARDIOTOXICITY; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEMODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MORPHOLOGY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BODY WEIGHT; BREAST NEOPLASMS; CELL LINE, TUMOR; COMET ASSAY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG TOXICITY; HEART; HEMODYNAMIC PROCESSES; HUMANS; LIPID PEROXIDATION; MALE; MELATONIN; MYOCARDIUM; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; TUMOR STEM CELL ASSAY;

EID: 23044442984     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000171750.97822.a2     Document Type: Article

References (52)

1. Singal PK, Siveski-Iliskovic N, Hill M, et al. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol. 1995;27:1055-1063.
2. Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs. 1994;47:223-258.
3. Han J, Kim C, Kim N, et al. The protective effect of melatonin administration against adriamycin-induced in rats. Kor J Physiol Pharmacol. 2001;5:333-342.
4. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987;19:817-828.
5. Wang YM, Madanat FF, Kimball JC, et al. Effect of vitamin E against adriamycin-induced toxicity in rabbits. Cancer Res. 1980;40:1022-1027.
6. Fujita K, Shinpo K, Yamada K, et al. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res. 1982;42:309-316.
7. Tesoriere L, Ciaccio M, Valenza M, et al. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharmacol Exp Ther. 1994;269:430-436.
8. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186-195.
9. Blask D. Melatonin in oncology. In Yu HS, Reiter RJ (eds): Melatonin. Boca Raton, FL: CRC Press, 1993:447-475.
10. Maestroni GJ. The immunoneuroendocrine role of melatonin. J Pineal Res. 1993;14:1-10.
11. Marshall KA, Reiter RJ, Poeggeler B, et al. Evaluation of the antioxidant activity of melatonin in vitro. Free Radic Biol Med. 1996;21:307-315.
12. Antolin RL, Rodriquez C, Saints RM, et al. Neurohormone melatonine prevents cell damage: effects of gene expression for antioxidant enzymes. FASEB J. 1996;10:882-890.
13. Reiter RJ, Tang L, Garcia JJ, et al. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. 1997;60:2255-2271.
14. Poeggeler B, Saarela S, Reiter RJ, et al. Melatonin-a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci. 1994;738:419-420.
15. Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol. 1998;56:339-384.
16. Reiter RJ, Tan DX, Kim SJ, et al. Melatonin as a pharmacological agent against oxidative damage to lipids and DNA. Proc West Pharmacol Soc. 1998;41:229-236.
17. Reiter RJ, Tan DX, Qi W. A brief survey of observations and mechanisms related to suppression of oxygen toxicity by melatonin. Acta Pharmacol Sin. 1998;19:575-581.
18. + channel activation by nitric oxide and protein kinase G in rabbit ventricular myocytes. Am J Physiol Heart Circ Physiol. 2002;283:H1545-H1554.
19. Okawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animals and tissues by thiobarbituric aid reaction. Anal Biochem. 1979;95:351-358.
20. Sestili P, Cantoni O. Osmotically driven radical diffusion of single-stranded DNA fragments on an agarose bed as a convenient measure of DNA strand scission. Free Radicals Biol Med. 1999;26:1019-1026.
21. Herman EH, Zhang J, Ferrans VJ. Comparison of the protective effects of desferrioxamine and ICRf-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol. 1994;35: 93-100.
22. Koning J, Palmer P, Franks CR, et al. Cardioxane-lCRF-187 towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev. 1991;18:1-19.
23. Ivanenko A, Crabtree VM, Tauman R, et al. Melatonin in children and adolescents with insomnia: a retrospective study. Clin Pediatr (Phila). 2003;42:51-58.
24. Weinberg LE, Singal PK. Refractory heart failure and age-related differences in adriamycin-induced myocardial changes in rats. Can J Physiol Pharmacol. 1987;65:1957-1965.
25. Tong J, Ganguly PK, Singal PK. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol. 1991;260:H909-H916.
26. Bonadonna G, Monfardini S, De Lena M, et al. Phase 1 and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res. 1970;30: 2572-2582.
27. Buja LM, Ferrans VJ, Mayer RJ, et al. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer. 1973;32:771-788.
28. Arena E, D'Alessandre N, Dusonchet L, et al. DNA, RNA and protein synthesis in heart, liver and brain of mice treated with daunorubicin and adriamycin. Int Res Commun Systemic Med Sci. 1974;2:1053-1061.
29. Bristow MR, Sageman WS, Scott RH, et al. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol. 1980;2:487-515.
30. Gosalvez M, van Rossum GD, Blanco MF. Inhibition of sodium-potassium- activated adenosine 5′-triphosphatase and ion transport by adriamycin. Cancer Res. 1979;39:257-261.
31. Singal PK, Segstro RJ, Singh RP, et al. Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Can J Cardiol. 1985;1:139-147.
32. 2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol. 1986;250:H419-H425.
33. Singal PK, Panagia V. Direct effects of adriamycin on the rat heart sarcolemma. Res Commun Chem Pathol Pharmacol. 1984;43:67-77.
34. Olson RD, MacDonald JS, vanBoxtel CJ, et al. Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin. J Pharmacol Exp Ther. 1980;215:450-454.
35. Kalyanaraman B, Perez-Reyes E, Mason RP. Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochim Biophys Acta. 1980;630:119-130.
36. Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res. 1983;43:4543-4551.
37. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation. 1994;89:2829-2835.
38. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977;197: 165-167.
39. Odom AL, Hatwig CA, Stanley JS, et al. Biochemical determinations of adriamycin toxicity in mouse liver, heart and intestine. Biochem Pharmacol. 1992;43:831-836.
40. Kumar D, Kirshenbaum L, Li T, et al. Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Ann N Y Acad Sci. 1999;874:156-168.
41. Kaul N, Siveski-Iliskovic N, Hill M, et al. Free radicals and the heart. J Pharmacol Toxicol Methods. 1993;30:55-67.
42. Iliskovic N, Hasinoff BB, Malisza KL, et al. Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy. Mol Cell Biochem. 1999;196:43-49.
43. Kumar D, Jugdutt BI. Apoptosis and oxidants in the heart. J Lab Clin Med. 2003;142:288-297.
44. Zhou S, Starkov A, Froberg MK, et al. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 2001;61: 771-777.
45. Xu MF, Ho S, Qian ZM, et al. Melatonin protects against cardiac toxicity of doxorubicin in rat. J Pineal Res. 2001;31:301-307.
46. de Graaf H, Dolsma WV, Willemse PH, et al. Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. Br J Cancer. 1997;76:943-945.
47. Mohamed HE, El-Swefy SE, Hagar HH. The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats. Pharmacol Res. 2000;42:115-121.
48. Mostafa MG, Mima T, Ohnishi ST, et al. S-Allylcysteine ameliorates doxorubicin toxicity in the heart and liver in mice. Planta Med. 2000;66: 148-151.
49. Nagi MN, Mansour MA. Protective effect of thymoquinone against doxorubicin-induced Cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res. 2000;41:283-289.
50. Qi W, Reiter RJ, Tan DX, et al. Inhibitory effects of melatonin on ferric nitrilotriacetate-induced lipid peroxidation and oxidative DNA damage in the rat kidney. Toxicology. 1999;139:81-91.
51. Granzotto M, Rapozzi V, Decorti G, et al. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J Pineal Res. 2001;31:206-213.
52. Lissoni P, Chilelli M, Villa S, et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res. 2003;35:12-15.